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safety conditions worsen to 20%. Therefore there is a need to organize trainings for 
administrative staffs and workers.
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Objectives: To describe and analyze specific aspects of pharmacoeconomic 
research and application in 10 Asian countries in recent years from 2003 to 
2013. MethOds: Our study concentrated on 10 Asian countries, including China, 
Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand 
and Vietnam. Literature was collected and reviewed systematically from United 
States National Library of Medicine- PubMed. Grey literature was also taken into 
account. After screening, a total of 268 pharmacoeconomic research articles and 
38 pharmacoeconomic application studies were included. This review followed the 
Cochrane systematic review guidelines and PRISMA flow diagram. Publication was 
analyzed by regions, economic evaluation techniques used, drug groups analyzed. 
The status of these pharmacoeconomic studies was identified with options being: 
for scientific interest, undertaken to support reimbursement issues directly or per-
formed in the framework of clinical guidelines or formularies. Results: There is 
an increasing in the number of pharmacoeconomic studies in Asian countries in 
the later period (2008-2013) compared with the first five years considered (2003-
2007). Most pharmacoeconomic studies were carried out in Japan (26%), China (22%), 
Thailand (15%), Taiwan (12%) and South Korea (10%). Cost-effectiveness analysis 
and cost-utility analysis were the most popular economic evaluation techniques 
used in 84% of total studies published. Antiinfectives for systemic use, antineo-
plastic and immunomodulating agents, nervous system and cardiovascular system 
drug groups were mostly researched and accounted for 41.79%, 19.78%, 10.45% and 
8.21%, respectively. Status of pharmacoeconomics applications varied among coun-
tries. cOnclusiOns: The number of pharmacoeconomic studies in Asia increased 
from 2008 onwards. The studies were mostly carried out in 5 specific countries (85% 
total) and concentrated to 4 specific drug groups. Types of pharmacoeconomics 
applications and research foci differ considerably amongst Asian countries.
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Objectives: The purpose of this study was to understand the drivers of the pricing 
premiums granted for submitting local RCT and / or local pharmacoeconomics (PE) 
data during the Taiwanese reimbursement assessment process. MethOds: The 11 
products that submitted local RCT and / or local PE data in their reimbursement 
submission to the NHIA between January 2012 and March 2014 were analysed in 
this study. Results: Of the 6 products that submitted local RCT data, 3 received 
the maximum 10% pricing premium for submitting these data. Abatacept was not 
granted any premium for not being a new molecule and benidipine hydrochloride 
was not granted any premium since its price comparator was an existing product 
that was already priced based on local data. Sorafenib has yet to receive a decision 
for the premium granted. Of the 7 products that submitted local PE data, 5 received 
a premium. 2 received a 1% and 2% premium respectively for submitting data with 
high uncertainty, 1 received a 2% premium for using inappropriate comparator dos-
age in the analysis, and 2 received a 5% premium for submitting data that were well 
accepted by the NHIA. 2 products did not receive any premium, as their data were 
considered to be incomplete or inappropriate. All of the submissions highlighted the 
product’s cost-effectiveness against the comparator. cOnclusiOns: A 10% pricing 
premium through local RCT data is likely achievable as long as the product with 
local RCT data is a new molecule whose comparator has not been priced based on 
its local data. On the other hand, achieving the maximum 10% pricing premium 
for submitting local PE data seems difficult to achieve; as of now, a 5% premium 
seems to be the maximum achievable. A premium as low as 1-2% is likely if there 
is any uncertainty in the data.
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Objectives: In Taiwan, the Second-Generation National Health Insurance (2G-NHI) 
Act was implemented since Jan. 1st, 2013. Thereafter, listing and reimbursement of 
new products are 2-stage assessments performed by the Expert Advisory Committee 
(EAC) and Pharmaceutical Benefits Reimbursement Scheme (PBRS) of National 
Health Insurance Administration (NHIA). EAC primarily evaluates clinical compara-
tive effectiveness and safety of new products, and assessments are rated as Category 
1 (substantial improvement), 2A (moderate improvement) or 2B (similar) compared 
to current standard therapy which are also used for pricing comparators. PBRS fur-
ther appraises the EAC’s suggestions and make final reimbursement recommenda-
tions. The objective of this study was to analyze the trends of the PBRS appraisals 
from Jan. 2013 to Feb. 2014 since implementation of the 2G-NHI Act. MethOds: 
A total of 33 new drugs underwent EAC assessments and PBRS appraisals were 
reviewed for their Categories. Further analysis was conducted to understand the 
trends based on the therapeutic indications and comparators. Results: There were 
21 new drugs granted reimbursement recommendations from PBRS joint meeting. 
Approximately 57% of them were rated as Category 2B, 38% as Category 2A, and only 
5% as Category 1. A new trend revealed that Category 2B new drugs were easier to 
be listed and reimbursed. The only Category 1 new product is an orphan drug in 
western countries used to mobilize haematopoietic stem cells for autologous trans-
and most important step that causes properly usage of such products as well as 
preventing the side effects from abuse of such products and for highly consumed 
products such as sunscreen cares and depilatories.
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Objectives: To implement the PSUR system in all wards of hospital. Reporting of 
PSURs for all the running newly launched drugs since 2011 in hospital periodically 
to DCG (I), New Delhi and assessment of the PSUR system functioning in the hospi-
tal. MethOds: Prospective observational study. Drug safety reporting either manual 
or through online portal. Preparation and submission of PSURs as per Schedule Y 
of drugs and Cosmetics act, India. Results: To implement the DCG (I) initiative 
PSUR program, one PSUR committee, one drug safety review panel and one Delphi 
panel for PSUR system assessment has been constituted. Drug safety reporting and 
assessment tools are prepared and validated. A manual reporting system of drug 
safety has been set up and one link on hospital intranet website will be very soon 
available for online drug safety reporting through each ward and departments of 
hospital. Necessary training on drug safety reporting is provided to all health care 
professionals. Online hospital information services are in use to track the prescrip-
tion of these drugs to the in-patients and then, these patients are extensively fol-
lowed for any drug related problem during their hospital stay. All the associated drug 
safety reports routed through wards to PSUR work station. The collected reports are 
assessed and coded using various scales, tools and softwares, e. g. Naranjo Scale, 
Hartwig severity scale and MedDRA coding software etc. PSUR system functioning 
in the hospital is assessed at regular time intervals through tool which is prepared 
and validated using Delphi technique. So far, since its inception two PSURs has 
been successfully submitted to DCG (I) at six months regular interval and third one 
is ready to report for next phase. cOnclusiOns: The present pioneering hospital 
based PSUR setup will create an environment for healthy safety reporting and helps 
the regulatory authorities for safety related decisions.
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Objectives: To study assessment and control the quality and the safety of hospi-
tals in Mongolia. MethOds: The research has been conducted by cross-sectional 
study by collecting information according to the quantitative and qualitative 
method. Results: In order to increase the quality and safety at the primary level 
hospitals the activity of special supporting (80.6%) and quality team control (66.7%) 
has been implemented, though, insufficient financing (33.3%) and professionals in 
quality control (19.4%) as well as special supporting activity has not been imple-
mented (91.7%). The special supporting activity (87.0%) has been implemented 
(p< 0.05) in the secondary level hospitals to increase the quality and safety, though, 
financing is insufficient (39.1%). The quality is conceptual idea, even though, this 
is a value that always could be felt and existed. The supporting activity (87.0%) and 
quality team (68.4%) are implemented (p< 0.05) to develop the quality in the tertiary 
level hospitals, however, other activities that develop quality are not implemented. 
The participants in the study answered about the challenging issues are high at all 
hospital levels, such as long queue to receive health service (54.5%-76.5%), overload 
in the hospital (67.6%-81.8%) and referral between hospitals (45.5% -72.2%) as well 
as hospital professionals are susceptible to illness (31.3%-52.2%). cOnclusiOns: 
Policy on quality and other related strategic documents are established 60-70% 
in the hospitals. Determination of health care and “determination of specialized 
health care standard through the diagnosis of the care” are insufficient at all level.
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Objectives: The purpose of the study was identifying the main problems of improv-
ing health care quality, organizational safety and human resource. MethOds: 
Questionnaire with 15 questions to study human resource potency. Financial state-
ment balance of 2007 and 2012. Questionnaire with 12 questions to study medical 
equipments potency Observational lists of internal and external environment safety 
of the hospitals Results: Totally 214 medical professionals were participated in 
the research: medical doctors 85 (39%), nurses 73 (34%), administration staff 16 (7%), 
and other staff 40 (19%). In 2007-2012 hospitals’ funding were increased up to 80%, 
whereas the number of birth increased up to 121%, number of surgeries increased up 
to 26% and number of inpatient clients up to 19%. It’s important to confirm the work 
position for medical equipment specialists and engineers according to the demands 
of medical equipment. cOnclusiOns: It is concluded that there is increasing need 
of consideration on the number of nurses, doctors and other health professionals. 
The result showed that it is urgent to run policy to assess the employees’ skills and 
supporting, appraising system should be open for everybody. Therefore 25% of the 
employees don’t recognize the organization mission, security policy and the deci-
sion making system is highly relevant to money. Amount of funding has improved 
but it still inadequate. Funding is still inadequate even it has improved between 
2007-2012. Domestic and foreign training is not enough for medical equipment 
specialists and engineers. Medical equipment technician’s skills are not adequate. 
Medical professionals’ knowledge about external and internal environment secu-
rity are ineffective. Hospitals external conditions got worse to 27% and internal 
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42 molecules which were sold in each country for the period. The countries were 
organised into the WHO regions. In total, around 1,000,000 unique national, product 
brands were accessed for the analysis. Results: Pharmaceutical price indices vary 
substantially between regions. The Asian regions recorded the lowest prices. The 
indices were as follows: South-East Asian Region D 0.21; South-East Asian Region 
B 0.31; European Region B 0.37 Western Pacific Region A; 0.44 European Region A 
0.45; African Region E 0.46; European Region C 0.49; Western Pacific Region B 0.51; 
Eastern Mediterranean Region D; 0.54; Region of the Americas D 0.87; Region of the 
Americas B 0.90; Eastern Mediterranean Region B 1.11. cOnclusiOns: This is the 
largest exercise ever undertaken in comparing international pharmaceutical prices. 
It also employs a more robust method than previous studies. The analysis shows 
Asian region pharmaceutical prices are the lowest in the world.
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Objectives: Review existing literature to understand the prevalent external price 
referencing (EPR) systems and to audit for directionality of the current mechanisms 
against the components defined in WHO/HAI (World Health Organization/Health 
Action International) project on EPR. MethOds: English publications between 
October 2000 and March 2013 investigating EPR systems were identified through 
EBM Reviews – Cochrane Database of Systematic Reviews, NHS Economic Evaluation 
Database; Embase; and MEDLINE searches. Publications on EPR systems were ana-
lyzed in three relevant groups. Qualitative analysis was done to audit the direction-
ality. Results: 101 out of 598 articles were found to be relevant and were placed and 
allocated into three relevant focus groups - 43 general, 44 individual country, and 14 
disease specific reference pricing articles. Regional distribution of publications was 
as follows: 49 RE (Region Europe), 12 Americas, and 15 Asia-Africa-Oceania. Number 
of publications over years was ranging from 3 to 10 with a significant peak in 2011 
at 21.52 articles were found to have directionality against the components defined 
in WHO/HAI project, and the use of several approaches for setting the price was 
commonly discussed. Use of EPR was discussed for both patented and generic drugs. 
Publications showed directionality towards use of several approaches for EPR and 
were directing the use of EPR for both patented and generic drugs. With regards to 
type of price level used, ex-manufacturer price was the dominant option. The for-
mula to derive the target price was directing towards average price. cOnclusiOns: 
There is a growing trend towards increase in number of publications on EPR with 
lead from RE. A number of discussions around the components raised on WHO/HAI 
Project indicate that it is a useful tool to lay out options for ERP. Growing number 
of publications will provide more robust evidence for commonly used options of 
each component.
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Objectives: In 2003, China introduced a heavily subsidized voluntary health insur-
ance program, the New Rural Cooperative Medical Scheme (NRCMS). This paper 
evaluates the effectiveness of the NRCMS by assessing its impact on health care 
utilization and out-of-pocket health expenditure. MethOds: We employ propensity 
score matching (PSM) with single difference and double difference based on data 
from China Health and Nutrition Survey (CHNS) from 1991 to 2009. To check the 
robustness of our results, we also use a bounding approach to test how strongly an 
invariant unobserved variable influences the selection process. For the out-of-pocket 
payments (OOP), a two-part model is used to correct for the large number of zero 
values and the skewness of the data. Results: We find no evidence of an increase 
in the utilization of formal medical care and preventive services. There is a large, 
positive effect on the utilization of village clinics, and large, negative effects in 
town hospitals, county hospitals and city hospitals. For the two-part model of out-
of-pocket (OOP) payments, we find a small, positive impact on the probability of 
positive OOP payments and a small, negative impact on the actual level of OOP pay-
ments. All the effects on the incidence of catastrophic medical payments based on 
different thresholds are insignificant. cOnclusiOns: The results indicate that the 
NRCMS did not increase the overall utilization but directs people from high-level to 
low-level medical facilities. The substitution effect among different levels of facili-
ties may be due to more generous reimbursement in low-level facilities. In addi-
tion, there is no reduction on the out-of-pocket medical payments or the incidence 
of catastrophic health payments. Therefore, the impact of NRCMS on increasing 
utilization and reducing financial risk is found to be limited. The lack of effective-
ness may be attributed to a relatively low premium and shallow benefit coverage.
PHP62
regulatory aPProval to Patient access, an evaluation of eu5 and us 
national timing differences
Mycka J.1, Dellamano R.2, Lobb W.1, Dalal N.1, Pereira E.1, Dellamano L.2, Sagaydachnaya O.1
1Medical Marketing Economics, LLC, Montclair, NJ, USA, 2ValueVector, Milan, Italy
Objectives: To examine the time between regulatory approval and launch/pricing 
and reimbursement (P&R) approval in the EU5 and US. MethOds: New molecular 
entities, formulations and combinations approved by the EMA between January 
2009 and December 2013 were included in the analysis. FDA approval dates were 
retrieved and launch dates were gathered as follows: USA: Date wholesale acquisi-
tion cost was effective; UK/Germany: Product availability/introduction; France: P&R 
decision (Agrément collectivités/date published in Journal Officiel); Italy: First P&R 
Decree publication on Official Gazette; Spain: Date of commercialization; and Time 
comparison for general medicines vs. orphan and oncology indications was made 
including shifts over time. Results: Time from approval to launch in the US aver-
plantation purpose. Almost all Category 2A new drugs fulfilled the unmet medical 
needs for infection control, tocolytic therapy in preterm labor, or new mechanism for 
cardiovascular disease. cOnclusiOns: Category 2B new drugs with less financial 
impact to NHI system seem easier to reach listing and reimbursement goal in the 
2-stage assessments. Reasonable budget impact and cost-effectiveness analysis are 
as important as robust comparative effectiveness data for PBRS appraisals. There is 
a need for long-term observation and further analysis.
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Objectives: The purpose of this study was to identify the main value drivers behind 
the innovation category designations (1, 2A, 2B) assigned during the Taiwanese 
reimbursement process. MethOds: All products assessed for reimbursement 
from January 2012 to March 2014 by the National Health Insurance Administration 
(NHIA) were considered in this analysis. The details of the assessments have been 
extracted from the NHIA meeting minutes and Center for Drug Evaluation (CDE) 
reports. Results: Category 1 designations are given to drugs that show “substantial 
clinical improvement”, Category 2A designations to drugs that exhibit “moderate 
improvement”, and Category 2B designations to drugs that provide similar clinical 
value to comparators. Since 2012,94 of 113 products received positive decisions 
from the NHIA. 19 received Category 2A (26%), 51 received Category 2B (71%), while 
2 received Category 1 (3%). Most Category 2B drugs were considered as alternative 
therapeutic options with similar efficacy (94%) to an existing product; others were 
considered to provide better clinical value but a larger budget impact or higher 
price (6%). Most Category 2A drugs were considered to provide additional efficacy, 
safety, or convenience over the comparator (53%). Of the 2 Category 1 products, 
plerixafor was rewarded for its curative potential in hematologic malignancies, as 
well as its potential reduction of hospitalisation costs; azacitidine was rewarded 
for being a first-in-class therapy for Myelodysplastic Syndrome. 22 of 94 products 
did not receive any category, as they were indication expansions. 17 of 113 assessed 
products received negative decisions due to their significant budget impact (59%) 
or lack of clinical benefit (41%). 2 out of 113 decisions are pending. cOnclusiOns: 
Both clinical and economic considerations heavily drive the assessment outcomes 
in Taiwan. In order to achieve a positive assessment outcome in Taiwan, a product 
needs to provide a combination of favourable clinical and economic data.
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Objectives: Pharmaceuticals can be marketed when regulatory approval has been 
obtained. However other barriers may need to be cleared before patients can gain 
access to subsidised medicines. In the Asia-Pacific region these subsidised systems 
are often government programmes and range from national tax funded schemes 
(Australian Pharmaceutical Benefits Schedule) through to coverage of a specific 
population (Thailand Social Security Scheme for office workers). Navigating these 
systems can be as simple as submitting a pricing application or as complex as a 
full scale societal health technology assessments. The aim of this study is to com-
pare the processes and timings between regulatory approval and subsidised access 
to medicines across the Asia-Pacific region. MethOds: Reimbursement guide-
lines from seven different jurisdictions in the Asia-Pacific region were reviewed. 
Differences in processes and time from regulatory approval to subsidised access 
were captured between Australia, China, Japan, Korea, New Zealand, Taiwan and 
Thailand. Results: Only Australia and Thailand allows evaluation of reimburse-
ment in parallel with regulatory evaluation. Parallel processing has been discussed 
in Korea and Taiwan but has not been implemented. The time between regulatory 
approval and subsidised access differs across jurisdictions. In general additional 
processes such as health economic evaluation, pricing negotiation, budget approval 
and administration prolong time to subsidised access well beyond 6 months post 
regulatory approval. Japan is unique as a reimbursement price should be published 
within 60 days after regulatory approval. cOnclusiOns: While most jurisdictions 
in the Asia-Pacific region differ in terms of regulatory and access approval pro-
cesses all but one of the jurisdictions included in this study require a regulatory 
approval letter before reimbursement can be sought. Parallel processing can shorten 
time for patients to access new medicines however other factors such as health 
economic evaluation, pricing negotiation, budget approval and administration are 
also important.
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Objectives: The study aimed to determine the differences between Asian and 
Global Pharmaceutical prices MethOds: The indices were developed using the 
Fisher Elteto, Koves, Szulc (EKS) method. The EKS method is widely used by the 
Organisation for Economic Co-operation and Development (OECD) but has not 
yet been applied to pharmaceutical prices. IMS MIDAS data was used to estimate 
prices and sales volumes. In order to construct the indices, the products needed 
to be defined as like. The definition of like in this study was based on molecules 
which are deemed to deliver equivalent health outcomes. The price indices were 
developed for countries in World Health Organisation (WHO) regions. The analysis 
compares prices across 56 countries over the period from 2005 to 2011 and included 
